Insmed, Inc. (NASDAQ:INSM)

CAPS Rating: 2 out of 5

Insmed Incorporated, a biopharmaceutical company, is focused on developing and commercializing novel, targeted inhalation therapies.

Recs

1
Player Avatar zzlangerhans (99.75) Submitted: 11/10/2011 7:55:06 PM : Outperform Start Price: $3.13 INSM Score: +6.64

Insmed stock has been volatile since the company first reported in August that the FDA had placed their phase III antibiotic on clinical hold due to a cancer signal in rat studies. The looming predicament of a non-existent pipeline is counterbalanced by the company's substantial cash reserves, 85M as of the last quarterly statement. The share price has been volatile, bouncing from 3 to 5 and back, and I've successfully red-thumbed twice. At the current low end of recent range, market cap of 77M is significantly lower than cash and I expect that cash position to provide a buffer to approaching broad market declines.

Featured Broker Partners


Advertisement